Biotech Values

[dewophile]

agree re fg-3019 (it has a new name now) for IPF is in the slow lane. a couple points to consider though are the fact they are requiring high res CT for eval of fibrosis so have to have access to that. the fact enrollment got stalled as drugs got approved for placebo portion so they had to go to geographies where soc wasn't available. lastly, they limited enrollment to mild to moderate pts
not quite sure how this compares to enrollment criteria for the ph 3 trials you describe